Docetaxel 75 / Cisplatin 75, Non-Small Cell Lung Carcinoma

Protocol-ID: 144 V1.1 (Short), DOCE75/CISP75, NSCLC

Indication(s)

Lung Carcinoma, Non-Small Cell; ICD-10 C34.-

Protocol classification

Classification: current standard
Intensity: Standard dose
Therapy mode: First line
Therapy intention: palliative

Cycles

Cycle length 21 days, recommended cycles: 6

Risks

Emetogenicity (MASCC/ESMO): high (>90%)
Neutropenia: very high (>41%)
Febrile Neutropenia: intermediate (10-20%)
Thrombocytopenia below 50 000/µl: low (<10%)
Anemia Hb below 8g/dl: moderate (6-15%)
Cardiotoxicity: low (<10%)

Therapy

Day	Substance	Dosage	Appl.	Procedure
AP Allergy prophylaxis: Docetaxel allergy prophylaxis, Dexamethasone
Access: - none -
Docetaxel SmPC
-1	Dexamethasone	8 mg	p.o.	1-0-1-0
From day before therapy with Docetaxel, antihistamine therapy not provided for in summary of product characteristics.

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
HYD Hydration: Hydration to Cisplatin (from 50 mg/m²)
Access: peripheral venous
Modified from Crona DJ et al 2017 and Hamroun A et al 2019.
1	Balanced Crystalloid Solution	3000 ml		i.v.	6 h	60 min before Docetaxel (d1)
Parallel to cisplatin and beyond. 20 mmol KCl and 4 mmol (10 ml) MgSO4 added to 1000 ml balanced crystalloid solution
1	Potassium chloride	60 mmol	none	i.v.	6 h	60 min before Docetaxel (d1)
1	Magnesium sulfate	12 mmol	none	i.v.	6 h	60 min before Docetaxel (d1)

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
AE Antiemesis: Emetogenicity high, FOSAP, GRAN i.v., DEXA i.v.
Access: peripheral venous
DGHO 2016, DKG 2016, MASCC/ESMO 2016
1	Fosaprepitant	150 mg	NaCl 0.9% 150 ml	i.v.	20 min	30 min before Docetaxel (d1)
1	Dexamethasone	12 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Docetaxel (d1)
1	Granisetron	1 mg	NaCl 0.9% 50 ml	i.v.	5 min	15 min before Docetaxel (d1)
or other 5-HT3 receptor antagonist
2-4	Dexamethasone	8 mg		p.o.		1-0-0-0
alternatively 4 mg 1-0-1

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
CTX Medical tumor therapy: CISP75/DOCE75
Access: peripheral venous
Palliative therapy in advanced NSCLC
1	Docetaxel	75 mg/m² BSA	NaCl 0.9% 250 ml	i.v.	60 min	Sequence
Give docetaxel concurrently with hydration before cisplatin.
1	Cisplatin	75 mg/m² BSA	NaCl 0.9% 500 ml	i.v.	60 min	Sequence

Day	Substance	Dosage	Appl.	Inf. time	Procedure
HW Hematopoietic growth factors: FN risk 10-20%, G-CSF long-acting, pegylated
Access: - none -
Risk of febrile neutropenia (FN) 10-20% and 1 risk factor: age > 65 y, laboratory parameters (anemia, lymphocytopenia < 700/µl, hypalbuminemia, hyperbilirubinemia) previous chemotherapy, comorbidities, low performance status, advanced symptomatic tumor disease (DKG 2016)
2	Pegfilgrastim	6 mg	subc	Bolus	24 h after Cisplatin (d1)
Use at risk: FN 10-20% and 1 risk factor, other long-acting G-CSF possible.

Day	Substance	Dosage	Appl.	Procedure
SUP Supportive therapy: Magnesium p.o.
Access: - none -
For magnesium substitution in cisplatin therapies from 50mg/m².
1-3	Magnesium	150 mg	p.o.	1-0-1-0
For Cisplatin-containing therapies, 150 mg Magnesium corresponds to about 6.2 mmol.

Concomitant therapy supplements

Dexamethasone of allergy prophylaxis is covered by dexamethasone of antiemesis on days 1 and 2.

References

Schiller JH, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer., N Engl J Med 2002 Jan 10;346(2):92-8 [PMID]
Millward MJ, Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer., J Clin Oncol. 1997 Feb;15(2):750-8 [PMID]
Fossella F, Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group, J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. [PMID]
Novello S, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol 2016 Sep;27(suppl 5):v1-v27 [PMID]

Recommendations

09/2021: European Society for Medical Oncology
02/2023: National Comprehensive Cancer Network

The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 22.02.2023